X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1040) 1040
science & technology (856) 856
life sciences & biomedicine (847) 847
male (606) 606
female (581) 581
middle aged (550) 550
hematology (544) 544
leukemia, myeloid, chronic-phase - drug therapy (529) 529
adult (525) 525
oncology (426) 426
chronic myeloid leukemia (393) 393
aged (374) 374
imatinib mesylate (339) 339
leukemia, myeloid, chronic-phase - genetics (300) 300
antineoplastic agents - therapeutic use (286) 286
pyrimidines - therapeutic use (283) 283
treatment outcome (273) 273
benzamides (253) 253
leukemia, myeloid, chronic-phase - pathology (251) 251
adolescent (233) 233
piperazines - therapeutic use (230) 230
chronic phase (204) 204
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (196) 196
protein kinase inhibitors - therapeutic use (190) 190
fusion proteins, bcr-abl - genetics (169) 169
leukemia, myeloid, chronic-phase - mortality (169) 169
leukemia, myeloid, chronic-phase - therapy (169) 169
imatinib (159) 159
young adult (157) 157
leukemia, myelogenous, chronic, bcr-abl positive - genetics (152) 152
leukemia, myelogenous, chronic, bcr-abl positive - pathology (145) 145
abridged index medicus (140) 140
aged, 80 and over (137) 137
prognosis (137) 137
leukemia (127) 127
follow-up studies (122) 122
pyrimidines - adverse effects (122) 122
pyrimidines - administration & dosage (113) 113
cml (110) 110
dasatinib (109) 109
hemic and lymphatic diseases (107) 107
remission induction (107) 107
antineoplastic agents - adverse effects (103) 103
leukemia, myelogenous, chronic, bcr-abl positive - therapy (98) 98
care and treatment (93) 93
antineoplastic agents - administration & dosage (91) 91
philadelphia chromosome (91) 91
interferon-alpha - therapeutic use (90) 90
time factors (90) 90
piperazines - adverse effects (89) 89
antineoplastic combined chemotherapy protocols - therapeutic use (88) 88
piperazines - administration & dosage (88) 88
survival analysis (88) 88
animals (87) 87
protein-tyrosine kinases - antagonists & inhibitors (87) 87
survival rate (86) 86
research (82) 82
leukemia, myeloid, chronic-phase - blood (80) 80
leukemia, myeloid, chronic-phase - diagnosis (80) 80
protein kinase inhibitors - administration & dosage (76) 76
drug resistance, neoplasm (75) 75
transplantation (74) 74
retrospective studies (73) 73
leukemia, myelogenous, chronic, bcr-abl positive - mortality (72) 72
leukemia, myeloid, chronic-phase - metabolism (72) 72
cancer (71) 71
protein kinase inhibitors - adverse effects (71) 71
antineoplastic agents (70) 70
blast crisis - pathology (69) 69
chronic myelogenous leukemia (69) 69
disease progression (68) 68
medicine & public health (67) 67
polymerase chain reaction (67) 67
transplantation, homologous (66) 66
child (65) 65
disease-free survival (65) 65
analysis (64) 64
nilotinib (64) 64
immunology (62) 62
drug therapy (61) 61
thiazoles - therapeutic use (60) 60
antimitotic agents (57) 57
hematology, oncology and palliative medicine (57) 57
prospective studies (55) 55
blast crisis - genetics (54) 54
bone marrow transplantation (54) 54
combined modality therapy (52) 52
pyrimidines - pharmacology (52) 52
benzamides - therapeutic use (50) 50
fusion proteins, bcr-abl - antagonists & inhibitors (50) 50
bone marrow - pathology (49) 49
hematopoietic stem cell transplantation (49) 49
risk factors (49) 49
biophysics (48) 48
blast crisis (48) 48
chronic myeloid leukaemia (48) 48
mutation (48) 48
in situ hybridization, fluorescence (46) 46
leukemia, myeloid, chronic-phase - complications (46) 46
tyrosine kinase inhibitor (46) 46
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1147) 1147
Japanese (53) 53
Chinese (31) 31
Portuguese (16) 16
Spanish (16) 16
German (10) 10
Russian (6) 6
French (5) 5
Polish (4) 4
Czech (2) 2
Turkish (2) 2
Croatian (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
The treatment of chronic myeloid leukemia (CML) achieved a great leap forward with the development of imatinib, a BCR-ABL kinase inhibitor. Alterations in the... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | Index Medicus | Abridged Index Medicus | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 4, pp. 761 - 767
Journal Article
Leukemia & lymphoma, ISSN 1042-8194, 06/2018, Volume 59, Issue 6, pp. 1312 - 1322
Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates,... 
chronic myelogenous leukemia | chronic phase | Ponatinib | salvage | accelerated phase | outcomes | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Leukemia, Myeloid, Accelerated Phase - pathology | Antineoplastic Agents - adverse effects | Treatment Failure | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Imidazoles - therapeutic use | Leukemia, Myeloid, Accelerated Phase - mortality | Pyridazines - adverse effects | Pyridazines - therapeutic use | Leukemia, Myeloid, Accelerated Phase - genetics | Leukemia, Myeloid, Accelerated Phase - drug therapy | Imidazoles - adverse effects | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Leukemia, Myeloid, Chronic-Phase - genetics | Index Medicus | ponatinib
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 25, pp. 6315 - 6321
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts | Index Medicus | Abridged Index Medicus
Journal Article
British journal of haematology, ISSN 0007-1048, 01/2015, Volume 168, Issue 1, pp. 69 - 81
Summary Bosutinib is an oral, dual SRC/ABL1 tyrosine kinase inhibitor for resistant/intolerant chronic myeloid leukaemia (CML). We assessed the efficacy and... 
BCR‐ABL1 | CML | tyrosine kinase inhibitor | bosutinib | chronic myeloid leukaemia | Chronic myeloid leukaemia | Tyrosine kinase inhibitor | Bosutinib | BCR-ABL1 | Life Sciences & Biomedicine | Hematology | Science & Technology | Piperazines - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Nitriles - administration & dosage | Benzamides - administration & dosage | Benzamides - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Odds Ratio | Benzamides - adverse effects | Aniline Compounds - administration & dosage | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Quinolines - therapeutic use | Aniline Compounds - therapeutic use | Mutation | Aniline Compounds - adverse effects | Nitriles - adverse effects | Quinolines - adverse effects | Nitriles - therapeutic use | Index Medicus | Haematological Malignancy
Journal Article
Leukemia, ISSN 0887-6924, 06/2008, Volume 22, Issue 6, pp. 1200 - 1206